APA (7th ed.) Citation

D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., . . . Streicher, H. (2018). Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials. The lancet oncology, 19(3), 416-426. https://doi.org/10.1016/S1470-2045(18)30006-8

Chicago Style (17th ed.) Citation

D'Angelo, Sandra P., et al. "Nivolumab with or Without Ipilimumab Treatment for Metastatic Sarcoma (Alliance A091401): Two Open-label, Non-comparative, Randomised, Phase 2 Trials." The Lancet Oncology 19, no. 3 (2018): 416-426. https://doi.org/10.1016/S1470-2045(18)30006-8.

MLA (9th ed.) Citation

D'Angelo, Sandra P., et al. "Nivolumab with or Without Ipilimumab Treatment for Metastatic Sarcoma (Alliance A091401): Two Open-label, Non-comparative, Randomised, Phase 2 Trials." The Lancet Oncology, vol. 19, no. 3, 2018, pp. 416-426, https://doi.org/10.1016/S1470-2045(18)30006-8.